NTRK1 and lung carcinoma: (Li et al.)[31] analyzed the application and research status of angiogenesis inhibitors in the treatment of lung cancer, and pointed out that the current anti-angiogenesis drugs targeting VEGF or receptor tyrosine kinase have a certain effect in the treatment of lung cancer.